Cardiovascular Efficacy of GLP ‐1 Receptor Agonists by Kidney Function: An Updated Meta‐Analysis of Randomized Trials Including the SOUL Trial
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.71035 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Masashi Hasebe und 3 weiteren Autor:innen. Beteiligte Einrichtung: Canada Excellence Research Chair Program in Genomic Medicine, McGill University, Montréal, Québec, Canada. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CIHR, Canada Research Chairs Program, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Aims
To evaluate the cardiovascular efficacy and absolute benefit of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) by baseline estimated glomerular filtration rate (eGFR). Materials and Methods PubMed and EMBASE were searched to 29 April 2026 for randomized placebo‐controlled trials of GLP‐1RAs in adults with type 2 diabetes or overweight/obesity that reported eGFR‐stratified major adverse cardiovascular events (MACE). Hazard ratios (HRs) were extracted for eGFR < 60 and ≥ 60 mL/min/1.73 m 2 . Random‐effects meta‐analyses estimated pooled HRs within each eGFR stratum and the pooled ratio of HRs (RHR) comparing eGFR < 60 versus ≥ 60 mL/min/1.73 m 2 . Exploratory absolute risk reduction (ARR) and number needed to treat (NNT) were derived from placebo‐group MACE risk and the corresponding pooled HR.
Results
Nine publications from eight trials were included, comprising 70 822 participants; 70 534 had eGFR‐stratified MACE data. GLP‐1RAs similarly reduced MACE risk among participants with eGFR ≥ 60 and < 60 mL/min/1.73 m 2 , with pooled HRs of 0.83 (95% CI 0.77–0.90; p < 0.001; I 2 = 35.6%) and 0.83 (95% CI 0.74–0.93; p < 0.001; I 2 = 40.9%), respectively. The pooled RHR showed no evidence of effect modification (1.02, 95% CI 0.85–1.21; p = 0.84). ARR was larger with eGFR < 60 than ≥ 60 mL/min/1.73 m 2 (2.6% vs. 1.6%), corresponding to NNTs of 39 (95% CI 26–91) versus 62 (95% CI 46–101).
Conclusions
GLP‐1RAs reduced MACE risk similarly across eGFR strata, while lower eGFR was associated with a larger estimated absolute cardiovascular benefit. These findings support GLP‐1RA therapy in individuals with reduced kidney function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Canada Excellence Research Chair Program in Genomic Medicine, McGill University, Montréal, Québec, Canada.
- Department of Human Genetics, McGill University, Montréal, Québec, Canada.
- Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan.
- Department of Diabetes and Endocrinology, Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-Kofukai, Osaka, Japan.
- Department of Population Health Sciences, University of Wisconsin-Madison, Madison, Wisconsin, USA.
ORCID-Profile: Masashi Hasebe, Chen-Yang Su, Daisuke Yabe, Satoshi Yoshiji
Förderung
- CIHR
- Canada Research Chairs Program
- Japan Society for the Promotion of Science
- McGill University
- DNA to RNA Foundational Program
- Canadian Institutes of Health Research
Zitieren
APA
Hasebe, M., Su, C. Y., Yabe, D., & Yoshiji, S. (2026). Cardiovascular Efficacy of GLP ‐1 Receptor Agonists by Kidney Function: An Updated Meta‐Analysis of Randomized Trials Including the SOUL Trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71035
Vancouver
Hasebe M, Su CY, Yabe D, Yoshiji S. Cardiovascular Efficacy of GLP ‐1 Receptor Agonists by Kidney Function: An Updated Meta‐Analysis of Randomized Trials Including the SOUL Trial. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71035
BibTeX
@article{Hasebe2026,
author = {Hasebe, Masashi and Su, Chen-Yang and Yabe, Daisuke and Yoshiji, Satoshi},
title = {Cardiovascular Efficacy of GLP ‐1 Receptor Agonists by Kidney Function: An Updated Meta‐Analysis of Randomized Trials Including the SOUL Trial},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.71035}
}
EUVIMED